{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-30206903-lixisenatide:v1","objectPathId":"pubmed-pmid-30206903-lixisenatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-30206903-lixisenatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30206903-lixisenatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30206903-lixisenatide-v1.md"},"story":{"slug":"pubmed-pmid-30206903-lixisenatide","version":1,"domain":"Literature metadata","dateInSource":"2023-05-22","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["lixisenatide"],"peptides":[{"slug":"lixisenatide","url":"https://peptidescanner.com/peptides/lixisenatide/"}]},"claims":[{"id":"headline","text":"Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…","sourceIds":["pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"]},{"id":"summary","text":"PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"]},{"id":"paragraph-1","text":"PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"]}],"sources":[{"id":"pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1","name":"PubMed","sourceClass":"A","title":"Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. · retained source version 1:2023-05-22:current:502cc3c3cdd1b02975408a6a37541b69f2c1124087ecd4220c5cf269bfa55ebb","url":"https://pubmed.ncbi.nlm.nih.gov/30206903/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"ab28f6471ac9cf214c10e58e3ded745cbb155e0fe3666e0ea550b268842299aa","tierARecordSha256":"765fb507f329601c98ff971b8a087acabd6f9eeb6945d997e57a057d7adc4453"},"integrity":{"algorithm":"sha256","contentSha256":"0595dcd2cfc69b41636fa9988cf543c540ec4d863c6eb2bd06495ee7d62d7f0b"}}